TPNS Technology Offered Only by ZOLL’s remedē System Listed in Newly Released Guideline for the Treatment of Central Sleep Apnea

Audio By Carbonatix

CHELMSFORD, Mass.--(BUSINESS WIRE)--Sep 9, 2025--

ZOLL ®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that transvenous phrenic nerve stimulation (TPNS) – the treatment currently available only by the ZOLL rem edē ® System – is now included in the updated American Academy of Sleep Medicine (AASM) guidelines for treatment of central sleep apnea (CSA).

The AASM recognizes the patient benefits of TPNS, highlighting the improvements in central event indices, oxygen desaturation index, quality of life, and several sleep architecture measures. TPNS is recommended both in primary central sleep apnea and central sleep apnea due to heart failure.

“The new guidelines call on clinicians to reframe central sleep apnea management, moving toward individualized care that centers on improving quality of life,” says Dr. Nancy Collop, Professor of Medicine, Director of the Emory Sleep Center and past President of the American Academy of Sleep Medicine. “TPNS is recognized as an important innovation backed by clinical data that shows a real patient benefit.”

TPNS is the only new therapy added to the guidelines since the last update in 2012. The AASM noted the development of TPNS and additional data on adaptive servo ventilation (ASV) as the primary drivers behind the updated guidelines. TPNS is also one of only two guideline-recommended therapies to show improved clinical outcomes in disease severity, excessive sleepiness, and cardiovascular health.

The AASM emphasizes a patient-centered approach in managing CSA. Rather than focusing solely on reducing breathing irregularities, the guidelines advocate for:

• Focus on patient-reported outcomes over disease process metrics: “Clinicians must prioritize optimizing therapy for the conditions contributing to central apneas and improving patient-reported outcomes rather than solely focusing on eliminating disordered breathing events.”1
• Consideration of alternative therapies for patients where central events persist: “Persistence of central respiratory events should prompt re-evaluation of the underlying risk factors and consideration of alternative treatment options.”1

ZOLL encourages sleep physicians to review the updated guidelines and include the rem edē System in treatment discussions with central sleep apnea patients. The updated AASM central sleep apnea guidelines can be found here.

Central sleep apnea occurs when the brain does not properly signal the body to stimulate a regular breathing pattern 2, and is a serious condition that is often associated with heart failure, coronary artery disease, and certain cardiac arrhythmias.

The rem edē ® System is an implantable device that automatically stimulates the phrenic nerve to stabilize breathing and is the first and only FDA-approved non-mask TPNS therapy for CSA. The rem edē ® System is clinically proven to improve sleep, breathing, and quality of life. Quality of life improvements were reported by 78% of rem edē ® patients after receiving their implant, and 95% reported that they would elect to have the procedure again 3.

For more information about the rem edē ® System, visit www.remede.zoll.com/tpns-csa-guidelines

About ZOLL

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Healthcare, Homes, and Material. Its healthcare operations include devices and systems for critical care, products and services for the manufacture of biotherapeutics, and a growing portfolio of specialty pharmaceuticals. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

Copyright © 2025 ZOLL Medical Corporation. All rights reserved. ZOLL and rem edē System are registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.

1 M. Safwan Badr, MD, MBA; Rami N. Khayat, MD; J. Shirine Allam, MD; et al. Treatment of central sleep apnea in adults: an American Academy of Sleep Medicine clinical practice guideline JCSM. 2025.
2 Costanzo M.R., Khayat R., Ponikowski P., et al. Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. J Am Coll Cardiol. 2015; 65:72–84.
3 Costanzo MR, Ponikowski P, Javaheri S, et al. Sustained Twelve Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. Am J Cardiol. 2018. pii: S0002-9149(18)30258-3. doi: 10.1016/j.amjcard.2018.02.022.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250909045522/en/

CONTACT: Matt Hogan

ZOLL

978-805-6561

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH TECHNOLOGY CARDIOLOGY SOFTWARE

SOURCE: ZOLL

Copyright Business Wire 2025.

PUB: 09/09/2025 09:00 AM/DISC: 09/09/2025 08:59 AM

http://www.businesswire.com/news/home/20250909045522/en